Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prothena Corp (PRTA)

Prothena Corp (PRTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 556,064
  • Shares Outstanding, K 53,830
  • Annual Sales, $ 135,160 K
  • Annual Income, $ -122,310 K
  • EBIT $ -255 M
  • EBITDA $ -252 M
  • 60-Month Beta -0.10
  • Price/Sales 3.93
  • Price/Cash Flow N/A
  • Price/Book 1.80

Options Overview Details

View History
  • Implied Volatility 57.78% (-16.48%)
  • Historical Volatility 50.32%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 339.95% on 11/19/25
  • IV Low 57.78% on 12/12/25
  • Expected Move (DTE 7) 0.85 (8.28%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 219
  • Put/Call OI Ratio 1.15
  • Today's Open Interest 29,729
  • Open Int (30-Day) 29,101
  • Expected Range 9.41 to 11.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.44
  • Number of Estimates 4
  • High Estimate -0.39
  • Low Estimate -0.57
  • Prior Year -1.08
  • Growth Rate Est. (year over year) +59.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.69 +5.88%
on 12/10/25
11.57 -11.32%
on 12/04/25
-0.59 (-5.44%)
since 11/12/25
3-Month
8.02 +27.93%
on 09/22/25
11.69 -12.23%
on 10/28/25
+2.05 (+24.97%)
since 09/12/25
52-Week
4.32 +137.50%
on 05/28/25
17.66 -41.90%
on 12/19/24
-3.55 (-25.71%)
since 12/12/24

Most Recent Stories

More News
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

TDP-43 CYTOPE ® preclinical data demonstrates the potential of Prothena’s CYTOPE technology as a novel modality for delivering large molecules into cells, enabling precise targeting...

PRTA : 10.37 (+0.39%)
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

Novo Nordisk’s Phase 2 data for coramitug supports ongoing Phase 3 CLEOPATTRA clinical trial in patients with ATTR amyloidosis with cardiomyopathy Coramitug is being developed by Novo...

PRTA : 10.37 (+0.39%)
Prothena: Q3 Earnings Snapshot

Prothena: Q3 Earnings Snapshot

PRTA : 10.37 (+0.39%)
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash position...

PRTA : 10.37 (+0.39%)
Prothena to Report Third Quarter 2025 Financial Results on November 6

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 10.37 (+0.39%)
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fast Track Designation recognizes the...

PRTA : 10.37 (+0.39%)
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 10.37 (+0.39%)
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

As previously communicated, Prothena plans to explore potential partnership interest to advance PRX012 and its preclinical PRX012-TfR (transferrin receptor) antibody ...

PRTA : 10.37 (+0.39%)
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3 ...

PRTA : 10.37 (+0.39%)
Prothena: Q2 Earnings Snapshot

Prothena: Q2 Earnings Snapshot

PRTA : 10.37 (+0.39%)

Business Summary

Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis...

See More

Key Turning Points

3rd Resistance Point 11.31
2nd Resistance Point 10.90
1st Resistance Point 10.62
Last Price 10.37
1st Support Level 9.93
2nd Support Level 9.52
3rd Support Level 9.24

See More

52-Week High 17.66
Fibonacci 61.8% 12.56
Fibonacci 50% 10.99
Last Price 10.37
Fibonacci 38.2% 9.42
52-Week Low 4.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar